Overview

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Ariad Pharmaceuticals
Treatments:
Sirolimus